JP2008500373A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500373A5
JP2008500373A5 JP2007515450A JP2007515450A JP2008500373A5 JP 2008500373 A5 JP2008500373 A5 JP 2008500373A5 JP 2007515450 A JP2007515450 A JP 2007515450A JP 2007515450 A JP2007515450 A JP 2007515450A JP 2008500373 A5 JP2008500373 A5 JP 2008500373A5
Authority
JP
Japan
Prior art keywords
myostatin
preparation
protein
amino acids
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007515450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018928 external-priority patent/WO2005115439A2/en
Publication of JP2008500373A publication Critical patent/JP2008500373A/ja
Publication of JP2008500373A5 publication Critical patent/JP2008500373A5/ja
Pending legal-status Critical Current

Links

JP2007515450A 2004-05-27 2005-05-27 ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 Pending JP2008500373A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57506204P 2004-05-27 2004-05-27
PCT/US2005/018928 WO2005115439A2 (en) 2004-05-27 2005-05-27 Cerberus/coco derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2008500373A JP2008500373A (ja) 2008-01-10
JP2008500373A5 true JP2008500373A5 (enExample) 2008-07-17

Family

ID=35451405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515450A Pending JP2008500373A (ja) 2004-05-27 2005-05-27 ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用

Country Status (8)

Country Link
US (4) US20100183695A1 (enExample)
EP (1) EP1755648A2 (enExample)
JP (1) JP2008500373A (enExample)
KR (1) KR20070026650A (enExample)
AU (1) AU2005247508A1 (enExample)
CA (1) CA2567810A1 (enExample)
IL (1) IL179602A0 (enExample)
WO (1) WO2005115439A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045553B2 (en) * 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
WO2008073351A2 (en) * 2006-12-08 2008-06-19 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
KR101672156B1 (ko) * 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
US20100233137A1 (en) * 2007-02-27 2010-09-16 Lanx, Inc. Compositions and Methods for Modification of Target Cells and to Their Uses Thereof
US20100150881A1 (en) * 2007-06-01 2010-06-17 Lanx, Inc. Compositions and Methods for Use of Scar Tissue in Repair of Weight Bearing Surfaces
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009105606A1 (en) * 2008-02-21 2009-08-27 Lanx, Llc Compositions and methods for use of scar tissue in repair of weight bearing surfaces
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US9149319B2 (en) * 2008-09-23 2015-10-06 Lanx, Llc Methods and compositions for stabilization of a vertebra
ES2593836T3 (es) 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
AU2010260145B2 (en) * 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
US20110129469A1 (en) 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
DE102010052941A1 (de) * 2010-11-18 2012-05-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutisches Protein
ES2907250T3 (es) 2012-01-27 2022-04-22 Biomarin Tech Bv Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
SMT202100008T1 (it) 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
WO2016008966A1 (en) * 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
IL305148A (en) 2015-09-15 2023-10-01 Scholar Rock Inc Anti-pro/hidden myostatin antibodies and their uses
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3785728A3 (en) * 2016-06-13 2021-04-28 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
JP7198757B2 (ja) 2017-01-06 2023-01-04 スカラー ロック インコーポレイテッド ミオスタチン活性化の阻害により代謝疾患を処置するための方法
CN109758616B (zh) * 2019-03-05 2021-11-19 中国医学科学院北京协和医院 一种新型促进骨再生材料及其制备方法
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998034951A1 (en) 1997-02-11 1998-08-13 Amrad Operations Pty. Ltd. A new cytokine family and uses thereof
AU726385B2 (en) 1997-04-29 2000-11-02 Regeneron Pharmaceuticals, Inc. Human cerberus protein
US5935852A (en) * 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU2586199A (en) 1998-02-05 1999-08-23 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000055193A2 (en) 1999-03-12 2000-09-21 Regeneron Pharmaceuticals, Inc. Human dan/cerberus related protein 6 (dcr6)
WO2002032929A2 (en) 2000-10-19 2002-04-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the cer1 gene
US20020159986A1 (en) 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
GB0111004D0 (en) 2001-05-04 2001-06-27 Univ Sheffield Screening method
US6513196B2 (en) * 2001-06-22 2003-02-04 Maytag Corporation Top cover hinge and method for using same
CN1161875C (zh) 2001-07-01 2004-08-11 周符明 开关稳功率电源
GB0118223D0 (en) 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
EP2053135A1 (en) 2001-10-31 2009-04-29 Alcon, Inc. Bone morphonic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
GB0130738D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Protein
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
CN1675365A (zh) 2002-06-14 2005-09-28 戴弗萨公司 木聚糖酶、编码木聚糖酶的核酸以及制备和应用它们的方法
KR20130036378A (ko) * 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
WO2004074460A2 (en) 2003-02-19 2004-09-02 The Rockefeller University Nucleotide and protein sequences of coc genes and methods based thereon

Similar Documents

Publication Publication Date Title
JP2008500373A5 (enExample)
CN112292144B (zh) 激活素受体iib型变体及其使用方法
US10730936B2 (en) Engineered anti-TGF-β antibodies and antigen-binding fragments
ES2361269T3 (es) Anticuerpos especificos de tgf beta 1.
US11090361B2 (en) Activin receptor type IIa variants and methods of use thereof
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
CA3009650A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja) 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
AU2012205384B2 (en) IL-27 antagonists for treating inflammatory diseases
EP2305715A2 (en) Monoclonal antibody to osteoprotegerin binding protein
US11484573B2 (en) Activin receptor type IIa variants and methods of use thereof
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
EA021425B1 (ru) Мутанты fgf21 и их применение
CN110177564A (zh) 多价的调节t细胞调节剂
JP2009545313A5 (enExample)
JP2018538356A (ja) 組織修復のための二重特異性治療用タンパク質
CN118159557A (zh) Sars-cov-2棘蛋白特异性抗体及其用途
TW201425339A (zh) 用於治療心臟衰竭之合成線狀愛帕琳（ａｐｅｌｉｎ）模擬物
US12329801B2 (en) Regenerative polypeptides and uses thereof
AU2014305658A1 (en) An antibody therapy for amyloid beta disease
AU2016332062A1 (en) Treatment of bile acid disorders
AU2007332819A1 (en) Uses of cerberus, coco and derivatives thereof
CN107531798A (zh) Pcsk9的抑制剂用于脂蛋白代谢病症的治疗
CN100413888C (zh) 可溶性多肽
JP2010521139A5 (enExample)